The Effects of Pemafibrate on Fibrinogen and Thrombogenicity in Patients with Coronary Artery Disease

20260 citationsJournal Articlediamond Open Access

Authors

Masanobu Ishii · Kumamoto University

Koichiro Fujisue · Kumamoto University

Koichi Kaikita · University of Miyazaki

Kenshi Yamanaga · Kumamoto Chuo Hospital

Shinsuke Hanatani · Kumamoto University

Y Matsuzawa · Kumamoto University

Mitsutoshi Miura · Fukuoka Tokushukai Hospital

Abstract

Pemafibrate significantly reduced fibrinogen levels in patients with CAD and hypertriglyceridemia, thus highlighting its primary benefit in lowering thrombotic risk.

Topics & Keywords

Blood properties and coagulation Antiplatelet Therapy and Cardiovascular Diseases Lipoproteins and Cardiovascular Health

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Atherosclerosis and Thrombosis

DOI: 10.5551/jat.65984

Field-Weighted Citation Impact: 0.00